Hacker News Board Hacker News, browsed like a classic message board
Live data from Hacker News

Pomegranate compound with anti-aging effects passes human trial

medicalxpress.com

Post reply on HN
Print view View original

1–10 of 52 posts

Re: Pomegranate compound with anti-aging effects passes human trial

#4

Post by strainer »

dannykwells wrote: post #2

Just fyi, the primary endpoint was safety, so to pass it just needed to not be toxic. The secondary endpoint was a biomarker of mitochondrial health. So no clinical effects are included here.

That seems overly dismissive of the finding on mitochondrial activity:

" The team then assessed the efficacy of UA by looking at cellular and mitochondrial health biomarkers in the participants' blood and muscle tissue. The results were compelling: UA stimulates mitochondrial biogenesis—the process by which cells increase mitochondrial mass—in the same way as regular exercise.

UA is the only known compound that re-establishes cells' ability to recycle defective mitochondria. "

Re: Pomegranate compound with anti-aging effects passes human trial

#5

Post by arkades »

1) Metabolic side effects tend to be slow and subtle. Vioxx caused increased heart attacks over time. Passing a phase 1 safety trial is fine and dandy, but it’s a far cry short of long-term safety in a drug targeting metabolism, and it’s not even where most drugs fail.

2) Lab evidence for a biomarker for a metabolic process is so far short of evidence of clinical improvement that it’s a joke. I will never stop deriding studies that point to proxy markers (or in this case, proxy proxy markers) as evidence of benefit. This has been proven to be inadequate so many times, across so many different studies, that it’s just not worth talking about anymore.

This is a perfectly fine and valid phase 1 study. It says “we have identified a dose range that doesn’t immediately sicken people.” That’s what phase 1 trials do. The rest is press release hype.

Re: Pomegranate compound with anti-aging effects passes human trial

#7

Post by fabian2k »

strainer wrote: post #4
dannykwells wrote: post #2

Just fyi, the primary endpoint was safety, so to pass it just needed to not be toxic. The secondary endpoint was a biomarker of mitochondrial health. So no clinical effects are included here.

That seems overly dismissive of the finding on mitochondrial activity: " The team then assessed the efficacy of UA by looking at cellular and mitochondrial health biomarkers in the participants' blood and muscle tissue. The results were compelling: UA stimulates mitochondrial biogenesis—the process by which cells increase mitochondrial mass—in the same way as regular exercise. UA is the only known compound that re-es…

Biomarkers are not a clinical effect, this doesn't tell you whether this compound has any anti-aging effects. This is still an early point in the development of a drug.

Re: Pomegranate compound with anti-aging effects passes human trial

#10

Post by utopcell »

arkades wrote: post #5

1) Metabolic side effects tend to be slow and subtle. Vioxx caused increased heart attacks over time. Passing a phase 1 safety trial is fine and dandy, but it’s a far cry short of long-term safety in a drug targeting metabolism, and it’s not even where most drugs fail. 2) Lab evidence for a biomarker for a metabolic process is so far short of evidence of clinical improvement that it’s a joke. I will never stop deridi…

Do all "we have identified a dose range that doesn’t immediately sicken people” studies make it to Nature journals ?
Post reply on HN